Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
p53 small molecule agonists, cell-based qHTS assay with human liver microsomes: Summary
Assay data:70 Active, 12 Activity ≤ 1 µM, 9667 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
p53 small molecule agonists, cell-based qHTS assay: Summary
Assay data:212 Active, 41 Activity ≤ 1 µM, 9667 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Same Project
p53 small molecule agonists, cell-based qHTS assay with rat liver microsomes: Summary
Assay data:103 Active, 14 Activity ≤ 1 µM, 9667 Tested
p53 small molecule agonists, cell-based qHTS assay
Assay data:87 Active, 5 Activity ≤ 1 nM, 180 Activity ≤ 1 µM, 9667 Tested
p53 small molecule agonists, cell-based qHTS assay with rat liver microsomes
Assay data:27 Active, 44 Activity ≤ 1 µM, 9667 Tested
p53 small molecule agonists, cell-based qHTS assay with human liver microsomes
Assay data:43 Active, 55 Activity ≤ 1 µM, 9667 Tested
KRAS G12C-GDP Exchange Assay from US Patent US20240109893: "PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR"
Assay data:22 Active, 8 Activity ≤ 1 nM, 22 Activity ≤ 1 µM, 22 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
SOS1 GDP TR-FRET Assay from US Patent US20240092803: "BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF"
Assay data:14 Active, 12 Activity ≤ 1 µM, 15 Tested
CK2 Alpha 1 Enzymatic Activity Inhibition from US Patent US11932606: "Anti-cancer/anti-fibrosis compounds"
Assay data:34 Active, 29 Activity ≤ 1 µM, 34 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
EGFR Kinase Assay from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:5 Active, 2 Activity ≤ 1 µM, 301 Tested
Biochemical Assay 3 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:314 Active, 144 Activity ≤ 1 µM, 367 Tested
Biochemical Assay 2 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:367 Active, 181 Activity ≤ 1 µM, 395 Tested
Biochemical Assay 1 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:372 Active, 198 Activity ≤ 1 µM, 401 Tested
Coupled Nucleotide Exchange Assay from US Patent US20240059703: "HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE"
Assay data:506 Active, 473 Activity ≤ 1 µM, 513 Tested
KRAS::SOS1 AlphaScreen Binding Assay from US Patent US20240051956: "SOS1 INHIBITORS AND USES THEREOF"
Assay data:85 Active, 87 Activity ≤ 1 µM, 87 Tested
SOS-Catalyzed Nucleotide Exchange Assay from US Patent US20240043448: "Small Molecule Inhibitors of KRAS G12C Mutant"
Assay data:93 Active, 7 Activity ≤ 1 nM, 83 Activity ≤ 1 µM, 93 Tested
MCF-7 Cell Growth Study from US Patent US20240043442: "SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF"
Assay data:50 Active, 30 Activity ≤ 1 nM, 50 Activity ≤ 1 µM, 50 Tested
Biological Assays gainst IRAK1 from US Patent US20240043405: "POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1"
Assay data:21 Active, 20 Activity ≤ 1 µM, 21 Tested
TBD from US Patent US20240034743: "TRICYCLIC COMPOUNDS AS EGFR INHIBITORS"
Assay data:135 Active, 118 Activity ≤ 1 nM, 137 Activity ≤ 1 µM, 137 Tested
Assay data:133 Active, 31 Activity ≤ 1 nM, 137 Activity ≤ 1 µM, 137 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on